Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ESMO
ESMO
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
BioSpace
ESMO
Novartis
prostate cancer
Pluvicto
radiopharmaceuticals
Flag link:
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
Fierce Biotech
ESMO
Daiichi Sankyo
AstraZeneca
Enhertu
patient deaths
clinical trials
non-small cell lung cancer
Flag link:
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
Flag link:
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
Fierce Biotech
ESMO
Ambrx
prostate cancer
ARX517
antibody-drug conjugate
Flag link:
Merck's early KRAS data suggest combination-friendly safety
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Flag link:
ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists
ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists
Fierce Pharma
ESMO
oncology
cancer
Europe
conferences
Flag link:
ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up
ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up
Fierce Pharma
ESMO
AstraZeneca
Merck
Lynparza
endometrial cancer
Flag link:
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
Fierce Pharma
ESMO
Pfizer
Seagen
cervical cancer
antibody-drug conjugate
Flag link:
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
Flag link:
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer
Fierce Pharma
Merck
GSK
Keytruda
Jemperli
ESMO
nonsquamous non-small cell lung cancer
Flag link:
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Flag link:
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer
Fierce Pharma
Seagen
Astellas
Merck
Padcev
Keytruda
bladder cancer
ESMO
Flag link:
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
BioSpace
Genentech
Alecensa
ALK inhibitors
non-small cell lung cancer
ESMO
Flag link:
After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review
Fierce Pharma
Gilead Sciences
breast cancer
Trodelvy
ESMO
FDA
priority review
Flag link:
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Merck
Keytruda
cancer
oncology
ESMO
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO
BioSpace
ESMO
Regeneron
Libtayo
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Merck
Keytruda
head and neck cancer
ESMO
Flag link:
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
A Post-mortem on the Failed Nektar-BMS Partnership at ESMO
BioSpace
ESMO
Bristol Myers Squibb
Nektar Therapeutics
Flag link:
Pages
1
2
3
4
5
6
next ›
last »